Verastem Gets FDA Fast-Track Approval on Lung Cancer Treatment
By Dean Seal
Verastem Oncology said federal regulators have granted their fast-track designation to a combination of the company's avutometinib with Amgen's sotorasib for the treatment of non-small cell lung cancer.
The Boston-based biopharmaceutical company said the special status from the Food and Drug Administration will fast-track the development of the combination for patients with KRAS G12C-mutant metastatic non-small cell lung cancer who have received at least one prior systemic therapy and haven't previously been treated with a KRAS G12C inhibitor.
The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
"Given that KRAS G12C is the most common KRAS mutation in NSCLC, the advancement of the combination is important in understanding potential new treatment approaches," Chief Executive Dan Paterson said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 18, 2024 16:31 ET (21:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom